In this activity, specialists from the multidisciplinary tumour board involved in the management of patients with NSCLC share their perspectives on the role of adjuvant EGFR-TKI therapy, the importance of biomarker testing and shared decision-making in early-stage NSCLC.
This activity has been designed to meet the educational needs of pulmonologists, oncologists, radiation oncologists, thoracic surgeons, pathologists and oncology nurse specialists practicing worldwide.
All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr David Planchard discloses: Advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Merck, Novartis, Pfizer and Roche.
Dr Masahiro Tsuboi discloses: Advisory board fees from AstraZeneca KK, Chugai Pharmaceutical Co, Merck Sharp & Dohme and Novartis; grants and research support from AstraZeneca, Boehringer Ingelheim Japan, Bristol Myers Squibb KK, Eli Lilly Japan, Merck Sharp & Dohme and Ono Pharmaceutical; speakers’ bureau for AstraZeneca KK, Bristol Myers Squibb KK, Chugai Pharmaceutical Co, Eli Lilly Japan, Johnson & Johnson Japan, Merck Sharp & Dohme, Ono Pharmaceutical and Taiho Pharma.
Prof. Johan Vansteenkiste discloses: Advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Merck Sharp & Dohme, Novartis, Pfizer and Roche; grants and research support from Merck Sharp & Dohme (institutional grant).
Prof. Albrecht Stenzinger discloses: Advisory board/speaker’s bureau fees/grants from AGCT, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Eli Lilly, Illumina, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, SeaGen, Takeda and Thermo Fisher Scientific.
Beth Sandy discloses: Consultant fees from Amgen; speaker’s bureau for AstraZeneca, Merck and Takeda Pharmaceutical Co.
Ryan N. Bookout, PharmD, BCOP discloses: Stocks (self-managed) from Bristol Myers Squibb, Gilead, Novartis and Spectrum Pharmaceuticals (all relationships terminated).
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit(s)™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 23 September 2021. Date credits expire: 22 September 2022.
If you have any questions regarding credit please contact firstname.lastname@example.org